证券代码：688073 证券简称：毕得医药 公告编号：2025-065 上海毕得医药科技股份有限公司 第二届监事会第十八次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 上海毕得医药科技股份有限公司（以下简称"公司"）第二届监事会第十八 次会议于 2025 年 7 月 15 日在公司会议室召开。本次会议由监事会主席蔡媚女士 召集并主持，会议应出席监事 3 名，实际出席监事 3 名。本次会议的召集、召开 及表决程序符合相关法律、行政法规、部门规章、规范性文件和《上海毕得医药 科技股份有限公司章程》的规定，会议决议合法有效。 二、监事会会议审议情况 经与会监事审议表决，形成的会议决议如下： 1、审议通过了《关于变更公司经营范围、取消监事会及修改<公司章程>并 办理工商变更登记的议案》 为了进一步完善公司治理结构，促进公司规范运作，根据 2024 年 7 月 1 日 起实施的《中华人民共和国公司法》及 2025 年 3 月 28 日起实施的《上市公司章 程指引（2025 年修订）》等法律法规 ...

证券代码：688073 证券简称：毕得医药 公告编号：2025-067 上海毕得医药科技股份有限公司 第二届董事会第二十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 上海毕得医药科技股份有限公司（以下简称"公司"）第二届董事会第二十 三次会议于 2025 年 7 月 15 日在公司会议室召开。本次会议由董事长戴岚女士召 集并主持，会议应出席董事 6 名，实际出席董事 6 名。本次会议的召集、召开及 表决程序符合相关法律、行政法规、部门规章、规范性文件和《上海毕得医药科 技股份有限公司章程》的规定，会议决议合法有效。 二、董事会会议审议情况 经与会董事审议表决，形成的会议决议如下： 1、审议通过了《关于变更公司经营范围、取消监事会及修改<公司章程>并 办理工商变更登记的议案》 为了进一步完善公司治理结构，促进公司规范运作，根据 2024 年 7 月 1 日 起实施的《中华人民共和国公司法》及 2025 年 3 月 28 日起实施的《上市公司章 程指引（2025 年修订）》等法律法规 ...

Summary of Conference Call Records Industry Overview - The global pharmaceutical industry is facing a significant patent cliff, with approximately $180 billion in annual revenue drugs set to lose patent protection between 2027 and 2028, representing nearly 12% of the global market share [3][4][10] - The domestic innovation industry chain is experiencing an increase in orders, particularly among upstream companies such as Baipusais, Bidai Pharmaceutical, and Bai'ao Pharmaceutical [1][5] - The CRO (Contract Research Organization) sector is seeing growth in companies like Zhaoyan New Drug, Yinuosi, and Tigermed, while the CDMO (Contract Development and Manufacturing Organization) sector is highlighted by strong performances from WuXi AppTec, Boteng Co., Tianyu Co., and Pro Pharma [1][5] Key Insights and Arguments - The recovery in the CXO (Contract Research Organization and Contract Development and Manufacturing Organization) sector is driven by increased domestic demand and a resurgence in orders, which is expected to translate into clinical research opportunities within 6 to 12 months [11][12] - The trend of innovation drug out-licensing (BD) is becoming more pronounced, as large pharmaceutical companies seek to diversify their pipelines and manage costs amid pressures from legislation such as the IRA (Inflation Reduction Act) [4][7] - Domestic listed companies have shown an increasing trend in R&D expenses as a percentage of revenue since the second half of last year, indicating a more proactive approach to R&D investment in response to market changes [8][10] Financial Performance and Trends - In the CDMO sector, WuXi AppTec reported a 47% year-on-year increase in orders by the end of last year, while Boteng Co. saw a 30% increase [11][13] - For the first half of 2025, WuXi AppTec's revenue is expected to grow by 21%, with a 44% increase in NON-IFRS net profit, while Boteng Co. is projected to achieve profitability after a turnaround [13] - The structure of R&D expenses in Biotech companies has shifted, with a notable increase in clinical trial costs, reflecting a conservative investment strategy amid market uncertainties [9] Potential Investment Opportunities - Recommended companies in the domestic innovation industry include Yinuosi, Zhaoyan New Drug, and Tigermed, as well as leading CDMO firms like WuXi AppTec and Pro Pharma [16] - The recovery in the domestic innovation industry is expected to create further investment opportunities, particularly as IPOs are being opened up and more companies are preparing to list [14] Additional Considerations - The overall recovery of the innovation industry chain is segmented into phases, with the current transition from phase 1.0 to 2.0 indicating a shift towards increased early-stage project investments by financially robust companies [10] - The competitive landscape of the domestic innovation industry chain should be assessed comprehensively, including comparisons with Indian and other overseas companies to better understand competitive advantages [17]

Group 1 - The A-share pharmaceutical sector experienced a strong upward trend in early trading, with significant gains in concepts such as CRO, recombinant proteins, and innovative drugs [1] - Companies like Medisi saw an increase of over 16%, while Bid Pharma rose more than 7%, with other stocks like Zhaoyan New Drug, Sunshine Nuohuo, and Nossger also following suit [1] - The National Development and Reform Commission announced that since the 14th Five-Year Plan, 402 new drugs have been added to the national medical insurance drug list [1]

Core Viewpoint - Bid Pharma (688073) has seen a significant increase in stock price, closing at 55.8 RMB, up 8.64% from the previous week, indicating positive market sentiment and potential growth opportunities [1] Company Announcements Summary - Bid Pharma has announced a share buyback plan, with the purpose of employee stock ownership plans or equity incentives [1] - As of June 30, 2025, the company has repurchased a total of 2,072,148 shares, representing 2.28% of its total share capital [1] - The company has adjusted the upper limit of its buyback price to not exceed 71.44 RMB per share, down from the previous limit of 72.30 RMB per share [2] - The buyback plan was first disclosed on February 8, 2025, and is set to be implemented from February 24, 2025, to August 23, 2025, with an expected buyback amount between 50 million to 100 million RMB [2] - The total amount spent on repurchases so far is approximately 94,147,819.45 RMB, with actual repurchase prices ranging from 37.47 RMB to 53.30 RMB per share [2]

Core Viewpoint - The company has announced an adjustment to the maximum repurchase price of its shares following the annual equity distribution for 2024, reducing it from RMB 72.30 per share to RMB 71.44 per share, effective from June 9, 2025 [1][3]. Group 1: Share Repurchase Details - The company plans to repurchase its shares through a centralized bidding method on the Shanghai Stock Exchange, with a total repurchase fund of no less than RMB 50 million and no more than RMB 100 million [2]. - The initial maximum repurchase price was set at RMB 72.30 per share, which has now been adjusted to RMB 71.44 per share due to the implementation of a cash dividend [3][4]. - The adjustment in the repurchase price is calculated based on the cash dividend per share, which is approximately RMB 0.86, and the change in circulating shares is zero since no new shares are issued [4]. Group 2: Financial Implications - With the adjusted maximum repurchase price of RMB 71.44 per share, the estimated number of shares to be repurchased at the upper limit of RMB 100 million would be approximately 1.4 million shares, representing about 0.77% of the company's total share capital [4]. - The company will adhere to relevant regulations during the repurchase period and will disclose information regarding the progress of the repurchase to investors [4].

上海毕得医药科技股份有限公司 关于 2024 年年度权益分派实施后调整回购价格上限 的公告 证券代码：688073 证券简称：毕得医药 公告编号：2025-061 上海毕得医药科技股份有限公司（以下简称"公司"）董事会于 2024 年 11 月 24 日收到公司实际控制人、董事长、总经理戴岚女士的《关于提议上海毕得 医药科技股份有限公司回购公司股份的函》，提议公司通过上海证券交易所交易 系统以集中竞价交易方式回购公司已发行的部分人民币普通股（A 股）股票。具 体内容详见公司于 2024 年 11 月 26 日在上海证券交易所网站（www.sse.com.cn） 披露的《关于公司实际控制人提议公司再次回购股份的提示性公告》（公告编号： 2024-049）。 公司分别于 2025 年 2 月 7 日、2025 年 2 月 24 日召开第二届董事会第十七 次会议、第二届监事会第十四次会议及 2025 年第三次临时股东大会，分别审议 通过了《关于以集中竞价交易方式回购公司股份方案的议案》，同意公司以集中 1 调整前回购价格上限：不超过人民币72.30元/股（含） 调整后回购价格上限：不超过人民币71.44元/股（含） ...

证券代码：688073 证券简称：毕得医药 公告编号：2025-062 上海毕得医药科技股份有限公司 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/2/8，由董事长提议 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 2 月 8 | 24 | 日~2025 | 年 | 月 | 23 日 | | 预计回购金额 | 5,000万元~10,000万元 | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | □用于转换公司可转债 □为维护公司价值及股东权益 | | | | | | | 累计已回购股数 | 2,072,148股 | | | | | | | 累计已回购股数占总股本比例 | 2.28% | | | | | | | 累计已回购金额 | 94,147,819.45元 | | | | | ...

截至2025年6月30日 13:30，上证科创板综合指数(000680)强势上涨1.51%，成分股翔宇医疗(688626)上涨 20.01%，华强科技(688151)上涨16.29%，晶品特装(688084)上涨15.29%，毕得医药(688073)，药康生物 (688046)等个股跟涨。科创综指ETF(589680)上涨1.56%，最新价报0.98元。 科创综指ETF(589680)，场外联接A：023757；联接C：023758；联接I：024141。 以上内容与数据，与有连云立场无关，不构成投资建议。据此操作，风险自担。 民生证券称，AI应用百花齐放，医疗、司法、金融、教育等具备广阔落地潜力。随着国产模型、国产 算力生态成熟，AI应用在多个垂直场景有望加速落地。以医疗为例，6月26日，蚂蚁集团推出全新的AI 健康应用"AQ"。基于蚂蚁的医疗大模型，AQ提供健康科普、就诊咨询、报告解读、健康档案等AI功 能，连接了全国超5000家医院、近百万医生、近200个名医AI分身等医疗服务。阿里、蚂蚁、字节、腾 讯等国内科技巨头纷纷入局，以模型能力为基石，联合拥有深刻行业Know-how的IT厂商，加速推进AI 应 ...

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry [1] Core Insights - The report highlights that the turning point for research services has arrived, with a focus on companies such as Haoyuan Pharmaceutical, Bidai Pharmaceutical, and Baiaosaitu [1] - The A-share pharmaceutical index has seen a decline of 6.3% this week and an increase of 4.6% year-to-date, underperforming the CSI 300 by 3.9% and outperforming it by 2.3% respectively [4][9] - The report emphasizes the positive impact of recent policies accelerating the development of innovative drugs, which benefits upstream companies involved in research and production [4][18] Summary by Sections Industry Trends - The A-share pharmaceutical index has decreased by 6.3% this week and increased by 4.6% year-to-date, while the H-share biotechnology index has dropped by 8.2% this week but increased by 48% year-to-date [4][9] - The report notes that the pharmaceutical sector has experienced significant declines, particularly in innovative drugs, with H-shares showing more pronounced drops due to previous high gains [4][9] Research and Development Progress - Recent policies have accelerated the approval processes for innovative drugs, with the FDA reducing NDA approval times from 10-12 months to 1-2 months, and China's CDE shortening IND review times from 60 days to 30 days [18][19] - The report indicates that the demand from the industrial sector is recovering, which will benefit early-stage research suppliers [20] Market Insights - The report suggests focusing on companies that are expected to benefit from the early-stage research demand, mergers and acquisitions, and the commercialization of innovative drugs [19] - Specific companies to watch include Haoyuan Pharmaceutical, Bidai Pharmaceutical, Baiaosaitu, and others in the life sciences service sector [4][19] Investment Strategy - The report recommends a ranking of sub-sectors for investment: innovative drugs > CXO > traditional Chinese medicine > medical devices > pharmacies > pharmaceutical commerce [11] - It highlights specific companies for investment based on growth potential, low valuations, and high dividend yields, particularly in the traditional Chinese medicine sector [11][13]